What works and what does not: Lessons from experience in a pharmaceutical company

QSAR and Combinatorial Science

Volumn 25, Issue 12, 2006, Pages 1192-1200

  Martin, Yvonne Connolly ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Deficiencies of global quantitative models; Expert systems; Predict mutagenicity; Predict octanol water log p

Indexed keywords

BIOCHEMISTRY; FORECASTING; SYNTHESIS (CHEMICAL);

COMPUTATIONAL CHEMISTS; DEFICIENCY OF GLOBAL QUANTITATIVE MODEL; DRUG RESEARCH; HIGH THROUGHPUT SCREENING; MOLECULAR PROPERTIES; MUTAGENICITY; PHARMACEUTICAL COMPANY; PREDICT MUTAGENICITY; PREDICT OCTANOL-WATER LOG P; QUANTITATIVE MODELS;

EXPERT SYSTEMS;

DIURETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; OCTANOL; WATER;

BIOAVAILABILITY; CALCULATION; CHEMICAL MODEL; COMPUTER SYSTEM; DRUG INDUSTRY; DRUG RESEARCH; EXPERIENCE; HIGH THROUGHPUT SCREENING; PKA; PRIORITY JOURNAL; PROBLEM SOLVING; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SCIENTIST; SHORT SURVEY; STRUCTURE ANALYSIS;

EID: 33845984006     PISSN: 1611020X     EISSN: 16110218     Source Type: Journal    
DOI: 10.1002/qsar.200610102     Document Type: Short Survey

References (40)

1. Daylight Chemical Information Systems, version 4.83. Daylight Chemical Information Systems, Aliso Viejo, CA 92656.
2. R. D. Brown, Y. C. Martin, J. Chem. Inf. Comput. Sci. 1996, 36, 572-584.
3. A. Ghose, G. Crippen, J. Comput. Chem. 1986, 7, 565-577.
4. R. Taylor, J. Chem. Inf. Comput. Sci. 1995, 35, 59-67.
5. Y. C. Martin, J. L. Kofron, L. M. Traphagen, J. Med. Chem. 2002, 45, 4350-4358.
6. Spotfire Decision Site, version 7.1.1., Spotfire Inc., Cambridge, MA 02139.
7. W. M. Meylan, P. H. Howard, J. Pharm. Sci. 1995, 84, 83-92.
8. M. E. Duban, M. G. Bures, J. DeLazzer, Y. C. Martin, in: B. Testa, H. v. d. Waterbeemd, G. Folkers, R. Guy (Eds), Pharmacokinetic Optimization in Drug Research, Wiley-VCH, Zurich, 2001, pp. 485-497.
9. Medchem 2002 Database, Biobyte, Claremont CA.
10. Pipeline Pilot, version 5.1.0.100, SciTegic, San Diego, CA.
11. Y. C. Martin, J. Med. Chem. 2005, 48, 3164-3170.
12. a DB, version 8.0., Advanced Chemistry Development Inc., Toronto, CA.
13. ADME Batch, version 1.5., Pharma Algorithms, Toronto CA.
14. C. A. Lipinski, F. Lombardo, B, W. Dominy, P. J. Feeney, Adv. Drug Delivery Rev. 1997, 23, 3-25.
15. D. E. Clark, J. Pharm. Sci. 1999, 88, 815-821.
16. U. Norinder, M. Haeberlein, Adv. Drug Delivery Rev. 2002, 54, 291-313.
17. P. Jones, D. Bariana, A. Fung, Y. Martin, J. Kyncl, A. Lall, US patent 4,058,559, 1977, 4-Aroyl Substituted Phenoxy Acetic Acids and Tetrazoles.
18. P. H. Jones, D. S. Bariana, A. K. L. Fung, Y. C. Martin, J. Kyncl, A. Lall, US patent 4,166,819, 1979, 4-Aroyl Substituted Phenoxy Methylene-5-Tetrazoles.
19. J. J. Plattner, C. M. Lee, B. W. Horrom, C. W. Ours, Y. C. Martin, A. G. Pernet, Abstracts of Papers of the American Chemical Society 184th National Meeting 1982, MEDI.
20. J. J. Plattner, Y. C. Martin, J. R. Smital, C. M. Lee, A. K. L. Fung, B. W. Horrom, S. R. Crowley, A. G. Pernet, P. R. Bunnell, K. H. Kim, J. Med. Chem. 1985, 28, 79-93.
21. P. H. Jones, J. H. Biel, C. W. Ours, I. J. Klundt, R. L. Lenga, Abstracts of Papers of the American Chemical Society 165th National Meeting 1973, MEDI009.
22. P. H. Jones, C. W. Ours, J. H. Biel, F. N. Minard, J. Kyncl, Y. C. Martin, Abstracts of Papers of the American Chemical Society 112th Meeting 1976, MEDIO 17
23. R. W. Schoenleber, J. W. Kebabian, Y. C. Martin, M. P. DeNinno, R. J. Ferner, D. M. Stout, C.-N. W. Hsiao, S. DiDomenico, Jr., J. F. DeBernardis, F. Z. Basha, M. D. Meyer, B. De, Abbott Laboratories, US patent 4,963,568, 1990, Dopamine Agonists.
24. Y. C. Martin, J. W. Kebabian, R. MacKenzie, R. Schoenleber, in: C. Silipo, A. Vittoria (Eds.), QSAR: Rational Approaches on the Design of Bioactive Compounds, Elsevier, Amsterdam, 1991, pp. 469-482.
25. M. R. DeNinno, R. Schoenleber, R. MacKenzie, D. R. Britton, K. E. Asin, C. Briggs, J. M. Trugman, M. Ackerman, L. Artman, L. Bedzarz, R. Bhatt, P. Curzon, E. Gomez, C. H. Kang, J. Stittsworth, J. W. Kebabian, Eur. J. Pharmacol. 1991, 199, 209-219.
26. Y. C. Martin, C. T. Lin, J. Wu, in: H. Kubinyi (Ed.), 3-D QSAR in Drug Design. Theory Methods and Applications, ESCOM, Leiden, 1993, pp. 643-660.
27. Y. C. Martin, C. T. Lin, in: C. G. Wermuth (Ed.), The Practice of Medicinal Chemistry, Academic Press, London, 1996, pp. 459-483.
28. Y. C. Martin, in: P. Bowen (Ed.), ACS Satellite TV Seminar: Molecular Modeling: The Small-Molecule Approach, American Chemical Society, Washington DC, 1994.
29. A. G. E. Wilson, A. C. White, R. A. Mueller, Curr. Opin. Drug Discovery Dev. 2003, 6, 123-128.
30. J. Ashby, R. W. Tennant, Mutat. Res. 1991, 257, 229-306.
31. R. Kho, J. A. Hodges, M. R. Hansen, H. O. Villar, J. Med. Chem. 2005, 48, 6671-6678.
32. United States National Library of Medicine, TOXNET Toxicology Data-Network, National Institutes of Health, Bethesda MD, 2006, Vol. 2006.
33. (33] Tox Boxes, 1.0: 1.0. Pharma Algorithms, Toronto CA.
34. R. D. Combes, P. Judson, Pestic. Sci. 1995, 45, 179-194.
35. W. H. Moos, G. D. Green, M. R. Pavia, Annu. Rep. Med. Chem. 1993, 28, 315-324.
36. P. Willett, V. Winterman, D. Bawden, J. Chem. Inf. Comput. Sci. 1986, 26, 109-118.
37. D. H. Patterson, R. D. Cramer, A. M. Ferguson, R. D. Clark, L. E. Weinberger, J. Med. Chem. 1996, 39, 3049-3059.
38. H. Matter, J. Med. Chem. 1997, 40, 1219-1229.
39. J. H. Van Drie, D. Weininger, Y. C. Martin, J. Comput. Aided Mol. Des. 1989, 3, 225-251.
40. Y. C. Martin, M. G. Bures, E. A. Danaher, J. DeLazzer, I. Lico, P. A. Pavlik, J. Comput. Aided Mol. Des. 1993, 7, 83-102.